Clinical trial
Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors
NCT06714617
Study timeline
Study start (actual)2025-04-10Date precision: day
Registry last updated2026-09-22
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Breast Cancer Stage IIIunresolved
HER2-positive Metastatic Breast Cancerunresolved
Unresectable Breast Carcinomaunresolved
Her2-Positiveunresolved
HER2 Gene Mutationunresolved
Gastroesophageal-junction Cancerunresolved
Non Small Cell Lung Cancerunresolved
Endometrial Neoplasmsunresolved
Peritoneal Cancerunresolved
Fallopian Tube Cancerunresolved
Ovarian Cancerunresolved
Urothelial Carcinoma Bladderunresolved
Solid Tumor, Adultunresolved
Gastric Cancerunresolved
Interventions
BL-M17D1DRUG
Sponsors & collaborators
SystImmune Inc.lead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06714617 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.